NASDAQ: CUE
Cue Biopharma Inc Stock Ownership - Who owns Cue Biopharma?

Insider buying vs selling

Have Cue Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daniel R. PasseriCHIEF EXECUTIVE OFFICER2024-12-1630,000$1.03
$30.90kBuy

1 of 1

CUE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CUE insiders and whales buy or sell their stock.

CUE Shareholders

What type of owners hold Cue Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bleichroeder LP8.87%6,819,164$5.35MInstitution
Gc Wealth Management Ria LLC4.34%3,331,644$2.62MInstitution
Vanguard Group Inc4.15%3,187,346$2.50MInstitution
Cameron Gray1.67%1,283,249$1.01MInsider
Aaron Gl Fletcher1.45%1,113,867$874.39kInsider
Michael J. Fox1.43%1,100,000$863.50kInsider
Christopher A. Marlett1.00%768,503$603.27kInsider
Geode Capital Management LLC0.90%692,173$543.36kInstitution
Robertson Stephens Wealth Management LLC0.62%478,500$375.62kInstitution
Blackrock Inc0.58%449,162$352.59kInstitution

1 of 3

CUE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CUE22.58%7.36%Net Buying
IMMX8.11%31.45%Net BuyingNet Buying
CLNN1.47%98.53%Net BuyingNet Selling
ACET62.39%19.44%Net Selling
COEP0.33%99.67%

Cue Biopharma Stock Ownership FAQ

Who owns Cue Biopharma?

Cue Biopharma (NASDAQ: CUE) is owned by 22.58% institutional shareholders, 7.36% Cue Biopharma insiders, and 70.06% retail investors. Cameron Gray is the largest individual Cue Biopharma shareholder, owning 1.28M shares representing 1.67% of the company. Cameron Gray's Cue Biopharma shares are currently valued at $1.00M.

If you're new to stock investing, here's how to buy Cue Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.